Center for Health Market Innovations (CHMI)

Programs

Close
Note: This profile is not complete and may contain incorrect or outdated information, including a missing or out of date contact. Do you have an update? Send a Change Request

Aspen Pharmacare

last updated Sep 27, 2011

Overview

Legal Status: 
Private (for-profit)
Year Launched: 
1997
Stage: 
Pilot/startup stage

Funding

Primary Source of Funding: 
Revenue (e.g., interest on loans)
Key program components: 

The need for antiretroviral treatment in South Africa is acute. Without significant changes, current projections indicate that 3.5million South Africans will die of AIDS-related infections by 2010. In 1997, Stephen Saad sold his shares in the Covan Zurich pharmaceutical company and, along with two others, founded Aspen Pharmacare with $7 million.

Its goal: to build a major pharmaceutical manufacturer capable of supplying the South African market with brand name, generic and over-the-counter medicines at affordable prices.

Aspen is now the largest producer of tablets and capsules in Africa, recording a net profit of $75 million in 2005. The case describes how Aspen's model and innovations have responded to a challenging environment, complicated by humanitarian, governmental and legal demands.

Hide this

Need help?

Using the CHMI Programs Database

  • Browse: Browse the database by applying one or more filters to narrow your search by characteristics. Click the "x" to remove any of the filters you've selected. Click "reset search" to remove all filters and start over.
  • Search: Search the database for a specific program by typing a name or keyword into the search box.
  • Add: If the program you're looking for is not in the CHMI database, submit the program to the CHMI pipeline by clicking here to add a program profile.
  • Update: If you notice incorrect or outdated information, or would like to help complete a profile for a CHMI pipeline program, request a change by clicking here, or at the top of the program profile.

Have a question? Check the FAQs first. Don’t see your question? Contact us.